{"schema_version":"secwatch.filing_event.v1","accession":"0001689375-23-000053","form_type":"8-K","ticker":"TRDA","cik":"0001689375","company_name":"Entrada Therapeutics, Inc.","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.861482+00:00","generated_at":"2026-06-12T02:17:14.505902+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Entrada Q2 cash $376.8M; on track to dose first participant in ENTR-601-44 Phase 1 in Sept 2023","bullets":["Cash, cash equivalents and marketable securities of $376.8M as of June 30, 2023, up from $188.7M at year-end 2022; cash runway extended through 2025.","Collaboration revenue of $18.2M in Q2 2023 (none in prior year); net loss $25.9M vs $23.2M.","Received MHRA and REC authorization for Phase 1 trial of ENTR-601-44 in healthy volunteers in UK; first dosing expected in September 2023 with data in H2 2024.","IND for ENTR-601-44 on clinical hold with FDA; update expected in Q4 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001689375-23-000053","json":"https://secwatch.observer/filing/0001689375-23-000053.json","markdown":"https://secwatch.observer/filing/0001689375-23-000053.md","text":"https://secwatch.observer/filing/0001689375-23-000053.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1689375/000168937523000053/0001689375-23-000053-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1689375/000168937523000053/trda-20230808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T02:17:14.505902+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f21122e2f2ec81591a8b09999f4605a2d3251e13","claim":"Entrada Therapeutics, Inc. reported second quarter 2023 results: net income Net loss was $25.9 million for the second quarter of 2023.","evidence_excerpt":"Net loss was $25.9 million for the second quarter of 2023, compared to a net loss of $23.2 million for the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937523000053/0001689375-23-000053-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter 2023"},{"label":"Net income","value":"Net loss was $25.9 million for the second quarter of 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"fcb48df4190de061ef5a0669e83c857ed070e43b","claim":"Entrada Therapeutics, Inc. reported second quarter 2023, quarter ended June 30, 2023 results: revenue 18.2 million, net income -25.9 million.","evidence_excerpt":"Collaboration revenue was $18.2 million for the second quarter of 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937523000053/0001689375-23-000053-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter 2023, quarter ended June 30, 2023"},{"label":"Revenue","value":"18.2 million"},{"label":"Net income","value":"-25.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}